Alaunos Therapeutics, Inc. cotiza a 3.03 USD y tiene una capitalización bursátil de $9M. En los últimos 12 meses ha facturado $3000 con un margen de flujo de caja libre del -59340.0%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company al…
| Periodo | 2025-08 | 2024-04 | 2023-11 | 2023-08 |
|---|---|---|---|---|
| Real | — | $-17.09 | $-4.41 | $-6.00 |
| Estimado | — | $-4.50 | $-5.25 | $-6.75 |
| Sorpresa | — | -279.8% | +16.0% | +11.1% |
| Métrica | TCRT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -84500.0% | -38.6% | -84461.4% |
| Net Margin | -83520.0% | -33.6% | -83486.4% |
| FCF Margin | -59340.0% | -13.9% | -59326.1% |
| ROE | -194.0% | -40.4% | -153.6% |
| ROA | -140.8% | -32.0% | -108.8% |
| Current Ratio | 2.45 | 2.84 | -0.39 |
| Debt / Equity | — | 0.28 | — |